Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in patients with systemic lupus erythematosus.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can be exacerbated by exposure to ultraviolet radiation (UVR). The number and phenotype of antigen presenting cells in the skin play a role in cutaneous immune response generation. Although antimalarials are widely used in SLE treatment, their mode of action is not completely elucidated. The aim of our study was to determine the effect of chloroquine treatment on HLA-DR+ and CD1a+ cell number in locally irradiated (three minimal erythema doses of UVB) and normal appearing skin in SLE patients and healthy subjects. A significantly higher number of HLA-DR+ and CD1a+ cells were found in both locations in SLE patients compared with controls. Following three months of daily chloroquine treatment (250 mg), the HLA-DR+ and CD1a+ cell counts were significantly reduced in both irradiated and unirradiated sites of SLE patients, although still higher than in controls. Chloroquine treatment reduces the number of antigen presenting cells in the skin of SLE patients, and this effect may explain the antimalarials beneficial immunoregulatory and anti-inflammatory properties.
Wozniacka
A
A
Department of Dermatology, Medical University of Lodz, Poland. wozniacka@bmp.net.pl
Lesiak
A
A
Narbutt
J
J
Kobos
J
J
Pavel
S
S
Sysa-Jedrzejowska
A
A
D000328:Adult; D000938:Antigen-Presenting Cells / Q000187:drug effects* / Q000276:immunology*; D018949:Antigens, CD1 / Q000097:blood*; D000962:Antimalarials / Q000627:therapeutic use*; D002738:Chloroquine / Q000627:therapeutic use*; D005260:Female; D006684:HLA-DR Antigens / Q000097:blood*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D018949:Antigens, CD1; D000962:Antimalarials; C419393:CD1a antigen; D006684:HLA-DR Antigens; D002738:Chloroquine